Here’s what you should know:
1. The FDA approved the first biosimilar, adalimumab-atto, in September 2016.
2. Cyltezo is approved to treat several diseases including: rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
3. Cyltezo is a tumor necrosis factor blocker.
4. Adverse events associated with adalimumab-atto include infections and malignancies. The most common events, however, are infections and injection-site reactions.
More articles on gastroenterology:
Florida jury finds gastroenterologist not liable in alleged ‘slapdash colonoscopy’ trial — 6 insights
Contaminated scopes used in 500+ patients at Buffalo VA
Renewed interest in gastroparesis research brings cure into focus
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.